Glycerol Phenylbutyrate (Ravicti®)

Assessment Status Assessment process complete
Drug Glycerol phenylbutyrate
Brand Ravicti®
Indication For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).
Assessment Process
Rapid review commissioned 26/03/2018
Rapid review completed 20/06/2018
Rapid review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement; August 2018